Senores
Committed to Global Wellness!

Date: August 26, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Outcome of Board Meeting of the Company held on Wednesday, August 26, 2026

Dear Sir/Madam,

With reference to the captioned subject, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e., Wednesday, August 26, 2026, has inter-alia, approved the following:

1. Appointment of Company Secretary and Compliance Officer of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mrs. Shilpa Sharma, an Associate Member of the Institute of Company Secretaries of India (Membership No.: A34516), as the Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company w.e.f. August 26, 2026.

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure- A.**

2. Appointment of Mr. Viranchi Arvindbhai Shah (DIN: 01598001) as the Non-Executive Additional Director (Independent Director) of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Viranchi Arvindbhai Shah (DIN: 01598001) as an Additional (Non- Executive Independent) Director of the Company, not liable to retire by rotation w.e.f. August 26, 2026 and shall hold shall hold office till the ensuing Annual General Meeting of the Company.

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure- B.**

3. Authority to determine materiality of an event or information and disclosure to Stock Exchanges

In terms of Regulation 30(5) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the following Key Managerial Personnel have been appointed by the Board of Directors as the authorized officers of the Company to determine materiality of an event or information and for making disclosures thereof:

Name	Designation	Contact Details	Authorizations
Mr. Swapnil Jatinbhai Shah	Managing Director	**Registered Office:** 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054 **Tel.:** +91-79-29999857 **E-mail:** cs@senorespharma.com	To determine materiality of an event or information and for making disclosures to stock exchange(s).
Mr. Deval Rajnikant Shah	Whole Time Director and Chief Financial Officer (CFO)		
Mrs. Shilpa Sharma	Company Secretary and Compliance Officer	**Registered Office:** 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054 **Tel.:** +91-79-29999857 **E-mail:** cs@senorespharma.com	To make disclosures of an event or information to stock exchange(s).

4. Approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026 ("ESOS 2026"/" SCHEME")

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the adoption of the Senores Pharmaceuticals Employee Stock Option Scheme 2026 ("ESOS 2026"/"SCHEME") in accordance with the provisions of the Companies Act, 2013 and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, subject to the approval of the shareholders of the Company and such other regulatory/statutory approvals as may be necessary.

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure-C.**

5. Proposed incorporation of a Wholly Owned Subsidiary (WOS) in Mexico

The Board of Directors have accorded their approval for incorporation of a Wholly-Owned Subsidiary (WOS) in Mexico to support the Company's business and strategic objectives in the Mexican and other international markets.

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure-D.**

6. Proposed incorporation of a Subsidiary Company in Canada

The Board of Directors have accorded their approval for incorporation of a Subsidiary Company in Canada to support the Company's business and strategic objectives in the Canadian and other international markets. The investment in the proposed entity shall either be directly or through its Wholly Owned Subsidiary as per the Canadian applicable law.

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure-E.**

Kindly note that the meeting of Board of Directors of the Company commenced at 04:45 P.M. (IST) and concluded at 05:15 P.M. (IST).

This intimation and aforesaid information are also being uploaded on the Company's website at www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

SHILPA SHARMA
Digitally signed by SHILPA SHARMA
Date: 2026.08.26 18:35:52 +05'30'

Shilpa Sharma
Company Secretary & Compliance Officer
M.No.: A34516

Enclosures: As above

Annexure-A

Appointment of Company Secretary and Compliance Officer of the Company

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment of Mrs. Shilpa Sharma (Membership No.: A34516) as the Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company w.e.f. August 26, 2026.
2.	Date of appointment~~/re-appointment/cessation (as applicable) and term of appointment~~	August 26, 2026
3.	Brief Profile (in case of appointment)	Mrs. Shilpa Sharma is a qualified Associate Member of the Institute of Company Secretaries of India (ICSI) and holds a Bachelor's degree in Law and Commerce from the University of Rajasthan. She brings over 13 years of extensive experience in the corporate sector, including more than 10 years of experience with BSE- and NSE-listed companies. Over the course of her career, Shilpa has developed strong expertise in corporate governance, securities law, listed-company compliances, and complex corporate actions. She has played a key role in several significant transactions, including capital restructuring, mergers and amalgamations, reverse mergers, demergers, rights issues, ESOP, Qualified Institutional Placements (QIPs), preferential allotments, capital reductions, and revocation of suspension of listed entity. She has also been involved in the acquisition of companies through the Insolvency and Bankruptcy Code (IBC) framework. With her extensive experience in listed entities and complex corporate transactions, she brings a strong combination of technical expertise, regulatory knowledge, corporate governance acumen, and strategic execution capabilities.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Annexure -B

Appointment of Mr. Viranchi Arvindbhai Shah (DIN: 01598001) as the Non-Executive Additional Director (Independent Director) of the Company

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment of Mr. Viranchi Arvindbhai Shah (DIN: 01598001) as the Non-Executive Additional Director (Independent Director) of the Company w.e.f. August 26, 2026.
2.	Date of appointment~~/re-appointment/cessation (as applicable)~~ and-term of appointment	August 26, 2026 Appointed as a Non-Executive Additional Director (Independent Director) for the first term of 5 (Five) consecutive years, not liable to retire by rotation and shall hold office till the ensuing Annual General Meeting of the Company.
3.	Brief Profile (in case of appointment)	Dr. Viranchi Arvindbhai Shah is a pharmacist, entrepreneur and prominent pharmaceutical industry leader with over 25 years of experience in the pharmaceutical sector. His professional journey spans entrepreneurship, industry representation, policy engagement, international trade promotion, pharmaceutical education and institution building. A Gold Medalist from L. M. College of Pharmacy, Dr. Shah subsequently pursued an MBA and earned a Ph.D. in Business Administration. He is a Promoter and Director of the Saga Group, a family-promoted pharmaceutical enterprise with a legacy of over 45 years in the industry. Dr. Shah has played an active leadership role in some of India's leading pharmaceutical industry associations. He currently serves as the National Spokesperson of the Indian Drug Manufacturers' Association (IDMA) and earlier served as its National President for three consecutive years, from 2022 to 2024. During his long association with IDMA, he has contributed extensively to industry dialogue on regulatory policy, pharmaceutical manufacturing, exports, compliance and sectoral development Through his diverse engagements, Dr. Shah brings together entrepreneurship, pharmaceutical industry leadership, Government policy engagement, international trade promotion,

		education, innovation and institutional service, making him a respected voice within India's pharmaceutical ecosystem.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Dr. Viranchi Arvindbhai Shah is not related inter-se to any other Directors of Company.
5.	Information as required under BSE circular no. LIST/COMP/14/2018- 19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018	Dr. Viranchi Arvindbhai Shah is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Annexure-C

Approval of Senores Pharmaceuticals Employee Stock Option Scheme 2026 ("ESOS 2026"/" SCHEME")

Sr. No.	Disclosure Requirement	Details
1.	Brief details of options granted	4,72,000 (Four Lakh and Seventy- Two Thousand) employee stock options ("Options") to be granted to the eligible employees as determined by the Nomination and Remuneration Committee ("Committee").
2.	Whether the scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.	Yes, Senores Pharmaceuticals Employee Stock Option Scheme 2026 ("ESOP 2026"/" SCHEME"), is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
3.	Total number of shares covered by these options	The total number of Options to be granted under ESOS 2026 is 1% of the existing equity on fully diluted basis, i.e. 472,000 (Four Lakh and Seventy-Two Thousand) Options. Each Option when exercised would be converted into one equity share of face value of Rs. 10/- (Rupees Ten) each fully paid-up.
4.	Pricing formula	Not Applicable as no grant being done at present. However, the exercise price per Option shall be determined by the Committee at the time of grant subject to a discount up to 50% (Fifty Percent) from the market price of the Share as on the grant date.
5.	Options vested	Not Applicable at this stage.
6.	Time within which option may be exercised	The exercise period in respect of a vested Option shall be subject to a maximum period of 4 (Four) years commencing from the date

		of vesting of such Option or such other shorter period as determined by the Committee.
7.	Options exercised	Not Applicable at this stage.
8.	Money realized by exercise of options	Not Applicable at this stage.
9.	The total number of shares arising as a result of exercise of option	Not Applicable at this stage.
10.	Options lapsed	Not Applicable at this stage.
11.	Variation of terms of option	Not Applicable.
12.	Brief details of significant terms	• The Options granted under the Scheme shall vest not earlier than minimum vesting period of 1 (One) year and not later than maximum vesting period of 4 (Four) years from the grant date. • The maximum number of Options that may be granted per employee per grant and in aggregate of all grants taken together for such employee under ESOS 2026 shall be 1,18,000 (One Lakh Eighteen Thousand) Options. • The Shares issued pursuant to exercise of Options shall not be subject to any lock-in period restriction except such restrictions as may be prescribed under the applicable laws including that under the code of conduct framed, if any, by the Company under the Securities and Exchange Board of India (Prohibition of Insider Trading), Regulations, 2015, as amended. • The Nomination and Remuneration Committee ("Committee") of the Company shall supervise and administer the Scheme. All questions of interpretation of the Scheme shall be determined by the Committee as per the terms of the Scheme and such determination shall be final and binding upon all persons having an interest in the Scheme. • An employee of the Company, subsidiary company, in India or outside India as defined under the scheme may participate in the Scheme subject to appraisal process for determining the eligibility of employees more specifically as stated in the Scheme.
13.	Subsequent changes or cancellation or exercise of such options	Not Applicable

14.	Diluted earnings per share pursuant to issue of equity share on exercise of options.	Not Applicable

Annexure -D

Proposed incorporation of a Wholly Owned Subsidiary (WOS) in Mexico

Sr. No.	Disclosure Requirement	Details
1.	Name of the entity, date & country of incorporation, etc	Name of entity and Date of incorporation: Not applicable as entity is yet to be incorporated Proposed country of incorporation: Mexico
2.	Name of holding company of the incorporated company and relation with the listed entity	The entity proposed to be incorporated will be a Wholly Owned Subsidiary (WOS) of Senores Pharmaceuticals Limited ('Company').
3.	Industry to which the entity being incorporated belongs	Pharmaceutical Industry
4.	Brief background about the entity incorporated in terms of products / line of business	The WOS is proposed to be incorporated with the primary objective to undertake the business of supply and distribution of pharmaceutical product in Mexican market and to support the Company's business and strategic objectives in the Mexican and other international markets.
5.	Brief details of any governmental or regulatory approvals required for the incorporation	As per the regulatory/statutory laws prevailing in Mexico.
6.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration. Company shall subscribe to 100% of the initial paid-up share capital of the WOS in cash.
7.	Cost of subscription / price at which the shares are subscribed	Not applicable as entity is yet to be incorporated
8.	Percentage of shareholding / control by the listed entity and / or number of shares allotted	Company will hold 100% shareholding of the proposed WOS.

Annexure -E

Proposed incorporation of a Subsidiary Company in Canada

Sr. No.	Disclosure Requirement	Details
1.	Name of the entity, date & country of incorporation, etc	Name of entity and Date of incorporation: Not applicable as entity is yet to be incorporated. Proposed country of incorporation: Canada
2.	Name of holding company of the incorporated company and relation with the listed entity	Senores Pharmaceuticals Limited ('Company') either directly or through its Wholly Owned Subsidiary shall incorporate the proposed entity.
3.	Industry to which the entity being incorporated belongs	Pharmaceutical Industry.
4.	Brief background about the entity incorporated in terms of products / line of business	The proposed entity is to be incorporated with the primary objective to undertake the business of supply and distribution of pharmaceutical product in Canadian market.
5.	Brief details of any governmental or regulatory approvals required for the incorporation	As per the regulatory/statutory laws prevailing in Canada.
6.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration. The Company shall either directly or through its Wholly Owned Subsidiary may subscribe 51% or more of the initial paid-up share capital of the proposed entity.
7.	Cost of subscription / price at which the shares are subscribed	Not applicable as entity is yet to be incorporated.
8.	Percentage of shareholding / control by the listed entity and / or number of shares allotted	Company will hold 51% or more shareholding of the proposed entity.